Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyverna Therapeutics (KYTX) Change in Cash (2023 - 2026)

Kyverna Therapeutics posted quarterly Change in Cash of -$91.9 million for Q1 2026, down 131.19% year-on-year from $294.7 million in Q1 2025, and down 202.19% on a QoQ basis from $89.9 million in Q4 2025.

Kyverna Therapeutics (KYTX) has 4 years of Change in Cash data on file, last reported at -$91.9 million in Q1 2026.

  • For the quarter ending Q1 2026, Change in Cash fell 131.19% year-over-year to -$91.9 million; the trailing twelve-month figure through Mar 2026 stood at -$24.7 million (up 85.26% YoY), and the FY2025 full-year result was $27.5 million, down 55.66% from the prior year.
  • Change in Cash for Q1 2026 stood at -$91.9 million, down from $89.9 million in the prior quarter.
  • Across five years, Change in Cash topped out at $189.6 million in Q1 2024 and bottomed at -$92.7 million in Q2 2024.
  • The 4-year median for Change in Cash is -$8.1 million (2024), against an average of -$426461.5.
  • Peak annual rise in Change in Cash reached 9137.46% in 2024, while the deepest fall reached 779.06% in 2024.
  • A 4-year view of Change in Cash shows it stood at $11.7 million in 2023, then tumbled by 168.93% to -$8.1 million in 2024, then surged by 1216.58% to $89.9 million in 2025, then sank by 202.19% to -$91.9 million in 2026.
  • The last three Change in Cash figures came in at -$91.9 million (Q1 2026), $89.9 million (Q4 2025), and -$19.3 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Cash (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 2.44 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 623.00 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -2.44 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 417.10 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -153.10 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 53.61 Mn
10 Kyverna Therapeutics 497.98 Mn 265.03 Mn - -91.90 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -91.90 Mn
Dec 31, 2025 89.93 Mn
Sep 30, 2025 -19.28 Mn
Jun 30, 2025 -3.43 Mn
Mar 31, 2025 -39.75 Mn
Dec 31, 2024 -8.05 Mn
Sep 30, 2024 -26.97 Mn
Jun 30, 2024 -92.67 Mn
Mar 31, 2024 189.65 Mn
Dec 31, 2023 11.68 Mn
Sep 30, 2023 -30.46 Mn
Jun 30, 2023 13.65 Mn
Mar 31, 2023 2.05 Mn